Innovation Pharmaceuticals Inc (IPIX)

[rule_rationale]

"We believe we have identified the Mechanism of Action of Kevetrin which explains why Kevetrin™ is so effective in a broad spectrum of cancers," says Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. "Downregulation of HDAC2 also explains why Kevetrin™ is so effective in drug resistant tumors. Furthermore, since Kevetrin™ acts in a non-genotoxic manner and induces potent antitumor activity, we feel that Kevetrin™ is a clear standout from all other anticancer drugs. In all my years as a cancer researcher, I haven't seen a drug act like Kevetrin™ which is targeting and reacting with virtually every type of cancer."

[BEVERLY, MA--(Marketwire - Jan 17, 2012) - Cellceutix Corporation (OTCBB: CTIX)]

hmm... Is Celgene presenting at ASCO anything that lists wishes to study with HDAC2 inhibitors?